You are currently viewing Swiss Pharma Company – IDEOGEN takes over Special Access Program for BELEODAQ® (belinostat)
IDEOGEN Logo

Swiss Pharma Company – IDEOGEN takes over Special Access Program for BELEODAQ® (belinostat)

IDEOGEN GROUP, Managed Access division, takes over Special Access Program for BELEODAQ® (belinostat) in Europe, Middle East, North Africa, Russia, and CIS.

BELEODAQ® is a prescription medicine used to treat patients with a rare form of blood cancer called peripheral T-cell lymphoma (PTCL) that relapsed or does not respond to previous treatment. PTCL is a group of rare and aggressive non-Hodgkin lymphomas (NHL), a malignant lymphoproliferative disorder. PTCL accounts for approximately 10%-15% of all NHL cases.

BELEODAQ®(belinostat) is the only Histone Deacetylase Inhibitor (‘HDAC inhibitor’) globally to treat refractory/relapsed PTCL. The product received accelerated approval by the US Food and Drug Administration (‘FDA’) due to this rare disease’s high unmet medical need. 

Murat Göker, Chief Commercial Officer at Ideogen Group, commented: “Our modus operandi is to serve the unmet medical needs of patients at the Speed of Life. As the trusted partner, we service access for patients globally affected by underserved diseases. Our Special Access Programs allow physicians access to medicines like BELEODAQ® (belinostat) for special circumstances of individual patients when alternative treatment options are required. 

“We are privileged to be the exclusive fulfilment partner representing BELEODAQ® for immediate availability across many territories*. Due to the time-sensitive disease state of the relapsed/refractory PTCL patient, BELEODAQ®is warehoused in the EU and available for delivery  to any ordering pharmacist or physician within continental Europe with rapid deployment,” states Mehmet Göker, Chief Operations Officer.

Healthcare professionals can obtain details about the BELEODAQ® Special Access Program by calling an Ideogen representative at +800 22 44 77 00 or emailing healthcare@Ideogen.com.

Leave a Reply